Navitor Pharmaceuticals’ proprietary drug discovery platform is built on new insights into the mTORC1-mediated nutrient signaling pathway (Company Pipeline Navitor Pharmaceuticals, NOV 10, 2014, View Source [SID:1234500943]). As a critical regulatory pathway, mTORC1 is often dysregulated in multiple diseases across several important therapeutic areas, including lymphangioleiomyomatosis.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!